Search: onr:"swepub:oai:DiVA.org:uu-383878" > The Impact of Posit...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07453naa a2200709 4500 | |
001 | oai:DiVA.org:uu-383878 | |
003 | SwePub | |
008 | 190611s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3838782 URI |
024 | 7 | a https://doi.org/10.1097/SLA.00000000000025572 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Ghaneh, Paulau Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England;Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England4 aut |
245 | 1 0 | a The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma |
264 | 1 | c 2019 |
338 | a print2 rdacarrier | |
520 | a Objective and Background: Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapiesMethods: Analyses were carried out to assess the association between clinical characteristics and margin involvement as well as the effects of individual margin involvement on site of recurrence and overall and recurrence-free survival using individual patient data from the European Study Group for Pancreatic Cancer (ESPAC)-3 randomized controlled trial.Results: There were 1151 patients, of whom 505 (43.9%) had an RI resection. The median and 95% confidence interval (CI) overall survival was 24.9 (22.9-27.2) months for 646 (56.1%) patients with resection margin negative R0 >1 mm) tumors, 25.4 (21.6 30.4) months for 146 (12.7%) patients with RI <1 mm positive resection margins, and 18.7 (17.2-21.1) months for 359 (31.2%) patients with R1-direct positive margins (P < 0.001). In multivariable analysis, overall R 1-direct tumor margins, poor tumor differentiation, positive lymph node status, WHO performance status ≥ 1, maximum tumor size, and RI-direct posterior resection margin were all independently significantly associated with reduced overall and recurrence-free survival. Competing risks analysis showed that overall R1-direct positive resection margin status, positive lymph node status. WHO performance status 1, and R1-direct positive superior mesenteric/medial margin resection status were all significantly associated with local recurrence.Conclusions: RI-direct resections were associated with significantly reduced overall and recurrence-free survival following pancreatic cancer resection. Resection margin involvement was also associated with an increased risk for local recurrence. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
653 | a pancreatic cancer | |
653 | a recurrence | |
653 | a resection margins | |
653 | a surgery | |
653 | a survival | |
700 | 1 | a Kleeff, Jorgu Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England;Martin Luther Univ Halle Wittenberg, Univ Hosp Halle, Dept Surg, Halle, Germany4 aut |
700 | 1 | a Halloran, Christopher M.u Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England4 aut |
700 | 1 | a Raraty, Michaelu Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England4 aut |
700 | 1 | a Jackson, Richardu Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England4 aut |
700 | 1 | a Melling, Jamesu Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England4 aut |
700 | 1 | a Jones, Owainu Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England4 aut |
700 | 1 | a Palmer, Daniel H.u Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England4 aut |
700 | 1 | a Cox, Trevor F.u Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England4 aut |
700 | 1 | a Smith, Chloe J.u Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England4 aut |
700 | 1 | a O'Reilly, Derek A.u Manchester Royal Infirm, Dept Surg, Manchester, Lancs, England4 aut |
700 | 1 | a Izbicki, Jakob R.u Univ Hamburg, Dept Surg, Med Inst UKE, Hamburg, Germany4 aut |
700 | 1 | a Scarfe, Andrew G.u Univ Alberta, Dept Oncol, Div Med Oncol, Cross Canc Inst 2228, Edmonton, AB, Canada4 aut |
700 | 1 | a Valle, Juan W.u The Christie, Dept Med Oncol, Manchester, Lancs, England4 aut |
700 | 1 | a McDonald, Alexander C.u Beatson West Scotland Canc Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Carter, Rossu Glasgow Royal Infirm, Dept Surg, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Tebbutt, Niall C.u Austin Hlth, Dept Med Oncol, Melbourne, Vic, Australia4 aut |
700 | 1 | a Goldstein, Davidu Univ New South Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia;Univ New South Wales, Sch Clin, Sydney, NSW, Australia4 aut |
700 | 1 | a Padbury, Robertu Flinders Med Ctr, Dept Surg, Adelaide, SA, Australia4 aut |
700 | 1 | a Shannon, Jenniferu Nepean Canc Ctr, Dept Med Oncol, Nepean, ON, Australia;Univ Sydney, Sydney, NSW, Australia4 aut |
700 | 1 | a Dervenis, Christosu Agia Olga Hosp, Dept Surg, Athens, Greece4 aut |
700 | 1 | a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim |
700 | 1 | a Deakin, Marku Univ Hosp North Staffordshire, Dept Surg, Stoke On Trent, Staffs, England4 aut |
700 | 1 | a Anthoney, Alanu Univ Leeds, St Jamess Univ Hosp, Div Oncol, Leeds, W Yorkshire, England4 aut |
700 | 1 | a Lerch, Markus M.u Univ Med Greifswald, Dept Med A, Greifswald, Germany4 aut |
700 | 1 | a Mayerle, Juliau Univ Med Greifswald, Dept Med A, Greifswald, Germany4 aut |
700 | 1 | a Olah, Attilau Petz Aladar Hosp, Dept Surg, Gyor, Hungary4 aut |
700 | 1 | a Rawcliffe, Charlotte L.u Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England4 aut |
700 | 1 | a Campbell, Fionau Heidelberg Univ, Dept Surg, Heidelberg, Germany4 aut |
700 | 1 | a Strobel, Oliveru Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Pathol, Liverpool, Merseyside, England4 aut |
700 | 1 | a Buechler, Markus W.u Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Pathol, Liverpool, Merseyside, England4 aut |
700 | 1 | a Neoptolemos, John P.u Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England;Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England;Heidelberg Univ, Dept Surg, Heidelberg, Germany4 aut |
710 | 2 | a Univ Liverpool, Liverpool Canc Res, UK Canc Trials Unit, Liverpool, Merseyside, England;Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, Englandb Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England;Martin Luther Univ Halle Wittenberg, Univ Hosp Halle, Dept Surg, Halle, Germany4 org |
773 | 0 | t Annals of Surgeryg 269:3, s. 520-529q 269:3<520-529x 0003-4932x 1528-1140 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-383878 |
856 | 4 8 | u https://doi.org/10.1097/SLA.0000000000002557 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view